Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.79 |
| ▸ | LMNA | P02545 | 7/20 | 0.79 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26231049 | 0.86 | MAPT (0.62) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL9980456 | 0.86 | MAPT (0.77) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL15647116 | 0.84 | GAA (0.59) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL16038620 | 0.83 | MAPT (0.75) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL12066385 | 0.81 | MAPT (0.72) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL15648006 | 0.80 | GAA (0.60) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL1804039 | 0.80 | KDM4E (0.62) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL12067909 | 0.80 | MAPT (0.70) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL12065779 | 0.79 | LMNA (0.69) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL259406 | 0.78 | MAPT (0.69) | MAPTLMNAGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-102711474-B | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2014-09-10 | — | — | CN | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| CN-102791131-A | Compounds and methods | GLAXOSMITHKLINE LLC | 2012-11-21 | — | — | CN | disclosed |
| CN-102711474-A | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2012-10-03 | — | — | CN | disclosed |
| EP-2501233-A1 | QUINAZOLINE COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088031-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011056739-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | MCL1, BCLAF1, BCL2A1 | MAPT 4738/4885LMNA 4385/4885GAA 1302/4885 |
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | MAPT 3517/4885LMNA 2524/4885GAA 2320/4885 |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | MCL1, BCLAF1, BCL2A1 | MAPT 4738/4885LMNA 4385/4885GAA 1302/4885 |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | MAPT 2957/4885LMNA 3022/4885GAA 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.